Palliative Care, Advance Care Planning, Pain Management & End-of-Life
Key Takeaways
- Palliative care provides interdisciplinary symptom management concurrently with disease-modifying therapies at any stage of serious illness, whereas Hospice care requires a terminal prognosis <=6 months and foregoes curative interventions.
- Advance Care Planning utilizes Durable Power of Attorney for Healthcare for surrogate designation, Living Wills for general treatment preferences, and POLST/MOLST for actionable, portable medical orders signed by a clinician.
- Management of refractory dyspnea in palliative/end-of-life care centers on low-dose oral or IV opioids (e.g., morphine) to reduce breathlessness perception, alongside non-pharmacologic interventions like a cool fan blowing air across the face.
- Chronic pain pharmacotherapy in older adults emphasizes starting low and going slow, using topical NSAIDs or acetaminophen first line, while requiring a mandatory bowel regimen (stimulant laxative + stool softener) whenever initiating opioid therapy.
- End-of-life terminal phase care involves managing noisy respiratory secretions ('death rattle') with sublingual atropine or transdermal hyoscine/scopolamine, addressing delirium with low-dose haloperidol, and supporting family bereavement.
Palliative Care, Advance Care Planning, Pain Management & End-of-Life
1. Palliative Care vs. Hospice Care Delivery Models
Optimizing quality of life and relieving suffering in serious illness requires understanding the distinctions between palliative and hospice care delivery models.
Palliative Care Definition & Scope
Palliative care is specialized, interdisciplinary medical care focused on providing relief from the symptoms, pain, and stress of a serious, life-limiting illness (advanced heart failure, ESRD, COPD, ALS, metastatic cancer). The primary goal is improving quality of life for both patient and family.
- Key Feature: Palliative care is appropriate at any age and at any stage of a serious illness. It is delivered concurrently with disease-modifying, curative, or life-prolonging therapies (such as chemotherapy, radiation, hemodialysis, LVADs, or heart failure titrations). It is not dependent on prognosis.
Hospice Care Parameters & Eligibility
Hospice care is a specific delivery model and Medicare benefit structure for patients in the terminal phase of illness.
- Eligibility Criteria: Requires two physicians (or attending APRN and hospice medical director) to certify a terminal prognosis with life expectancy <=6 months if the disease runs its normal course.
- Care Philosophy: Patients and surrogates elect to shift goals entirely to comfort, voluntarily foregoing curative and disease-modifying treatments. Care is delivered by an interdisciplinary team in home, assisted living, nursing facility, or inpatient hospice.
2. Advance Care Planning & Legal-Ethical Instruments
Advance Directive Documents
- Durable Power of Attorney for Healthcare (DPOA-HC) / Healthcare Proxy: Designates a surrogate decision-maker authorized to make medical decisions if the patient loses capacity. It is the most adaptable advance directive for real-time decision-making in unforeseen clinical scenarios.
- Living Will: Written document specifying instructions regarding which life-sustaining medical treatments (CPR, mechanical ventilation, artificial nutrition/hydration, hemodialysis) should be withheld or withdrawn under specific conditions (terminal illness, persistent vegetative state).
- POLST / MOLST (Physician Orders for Life-Sustaining Treatment):
- Actionable medical orders signed by a licensed clinician (NP, PA, MD) and patient/surrogate.
- Portable across care settings: Immediately actionable by Emergency Medical Services (EMS) in home, transport, ED, or nursing facility. Dictates specific orders for CPR status, medical intervention level (Full vs. Selective vs. Comfort-Focused), and artificial nutrition.
Standards for Surrogate Decision-Making
- Substituted Judgment Standard (Primary): The surrogate must make the decision the patient would have made based on prior expressed wishes, values, and statements.
- Best Interest Standard (Secondary): Used only when patient wishes are completely unknown; surrogate decides what a reasonable person would choose as most beneficial.
3. Comprehensive Palliative Symptom Management
Refractory Dyspnea Management
Dyspnea is a subjective, distressing experience of air hunger common in advanced cardiopulmonary disease and terminal cancer.
- First-Line Pharmacotherapy: Low-dose systemic opioids (oral morphine 2.5–5 mg PO Q3–4H PRN, or low-dose IV morphine) are the gold standard for managing severe refractory dyspnea. Opioids blunt central dyspnea perception, reduce respiratory drive sensitivity to hypercapnia, and decrease pulmonary vascular congestion and anxiety.
- Oxygen Therapy: Supplemental O2 is indicated only if documented hypoxemia (SpO2 <90%) is present. Non-hypoxic dyspneic patients derive equal relief from room air delivered via nasal cannula.
- Non-Pharmacological: Directing a cool breeze from a handheld fan across the face (trigeminal nerve distribution) and head elevation.
Etiology-Targeted Antiemetic Selection
- Gastric Stasis / Delayed Emptying: Prokinetics (metoclopramide 5–10 mg PO TID).
- Chemotherapy / Toxin / Uremia: Serotonin antagonists (ondansetron 4–8 mg PO/IV) or central D2 antagonists (haloperidol 0.5–2 mg PO/IV).
- Bowel Obstruction / Visceral Secretions: Anticholinergics (scopolamine patch) or somatostatin analogs (octreotide).
4. Geriatric Pain Management & Opioid Prescribing
WHO Pain Ladder & Pharmacotherapy Rules
- Step 1 (Mild Pain 1–3): Non-opioid analgesics (acetaminophen, topical NSAIDs) +/- adjuvants (gabapentin for neuropathic pain).
- Step 2 (Moderate Pain 4–6): Low-dose strong opioids + non-opioids.
- Step 3 (Severe Pain 7–10): Strong opioids (morphine, oxycodone, hydromorphone, fentanyl) titrated to comfort.
Safety Rules & Beers Criteria 2023
- Acetaminophen: First-line for mild-to-moderate musculoskeletal pain. Max dose 2,000–3,000 mg/day in older adults.
- Oral NSAIDs: Avoid chronic use due to high risks of GI bleeding, renal failure, fluid retention, and heart failure exacerbation. Topical diclofenac gel is preferred for localized joint pain.
- Renal Impairment Caution: Morphine and meperidine produce active neurotoxic metabolites cleared by kidneys. In severe renal failure (eGFR <30 mL/min), morphine accumulates, causing severe sedation, respiratory depression, and myoclonus. Hydromorphone or Fentanyl are safer choices.
- Mandatory Bowel Regimen: Opioid-induced constipation is universal and non-tolerated (tolerance never develops). A prophylactic bowel regimen consisting of a stimulant laxative (senna 1–2 tabs daily) PLUS stool softener (docusate), or polyethylene glycol (Miralax) must be initiated concurrently at the time of the first opioid prescription.
5. Active Dying Phase & End-of-Life Interventions
Clinical Indicators of Active Dying
Recognizing the final 24 to 72 hours of life includes observing bedbound status, profound somnolence, diminished food/fluid intake, peripheral cyanosis and mottling of extremities, Cheyne-Stokes breathing, and oliguria.
End-of-Life Symptom Management
- Noisy Respiratory Secretions ("Death Rattle"): Caused by relaxation of hypopharyngeal muscles and inability to swallow secretions. Reassure family. Reposition patient to side-lying or elevate head of bed. Pharmacotherapy includes sublingual anticholinergic drops (sublingual atropine 1% ophthalmic solution 1–2 drops Q2–4H PRN) or transdermal scopolamine patch. Avoid deep oral suctioning, which causes severe distress and reflex secretion production.
- Terminal Delirium & Agitation: Restlessness or agitation during active dying. Evaluate for urinary retention or fecal impaction. Pharmacotherapy includes low-dose haloperidol (0.5–2 mg IV/SC/PO) or sublingual lorazepam.
Palliative & End-of-Life Matrix
| Domain | Key Clinical Marker | First-Line Intervention | Critical Caution |
|---|---|---|---|
| Hospice Benefit | Terminal prognosis <= 6 months | Interdisciplinary comfort care | Foregoes curative treatments |
| POLST Orders | Actionable medical order across settings | Dictates EMS CPR/intubation care | Must be signed by clinician |
| Refractory Dyspnea | Subjective breathlessness at end of life | Low-dose morphine + facial cool fan | O2 beneficial only if SpO2 <90% |
| Opioid Prescribing | Moderate-to-severe pain management | Hydromorphone/Fentanyl in CKD | MANDATORY concurrent senna + docusate |
| Death Rattle | Pooled subglottic secretions | Side-positioning; sublingual atropine | AVOID deep suctioning |
A 68-year-old male with end-stage heart failure (NYHA Class IV) is receiving optimal medical management, including IV diuretics and guideline-directed medical therapy. He reports severe, distressing dyspnea at rest despite having a normal oxygen saturation of 94% on room air. He expresses interest in receiving home symptom management without giving up his heart failure treatments. What is the most appropriate recommendation?
An APRN is preparing to discharge a 79-year-old male from the hospital with a new prescription for oral oxycodone 5 mg every 6 hours PRN for severe persistent pain secondary to lumbar vertebral compression fractures. Which medication regimen must be initiated concurrently with the opioid prescription?
A 74-year-old female with terminal pancreatic cancer is in the active dying phase in a inpatient hospice unit. Her family is distressed by the sudden onset of loud, gurgling, noisy respiratory secretions ('death rattle'). Physical exam shows she is un-arousable with shallow respirations. What is the most appropriate clinical intervention?
An 82-year-old male with end-stage renal disease (eGFR 18 mL/min) who has elected not to initiate hemodialysis requires opioid therapy for severe cancer-related bone pain. Which opioid analgesic is safest to prescribe to avoid neurotoxic metabolite accumulation in severe renal failure?